3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
2
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
5
Carcinoma, Transitional Cell
4
Ureteral Neoplasms
2
Urologic Neoplasms
1
Urethral Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoplasms
1
Metastatic Urothelial Cancer and Other Malignant Solid Tumors
1
Metastatic Urothelial Cancer
1
Interventions
Gemcitabine
6
Pemetrexed
3
Cisplatin
3
Carboplatin
3
atezolizumab
2
Trastuzumab
2
Sugammadex
2
Paclitaxel
2
Neostigmine
2
vinflunine
1
poly ICLC
1
pembrolizumab
1
motexafin gadolinium
1
montanide ISA 51
1
flt3 ligand protein
1
enfortumab vedotin
1
delta 24-sterol reductase
1
daratumumab
1
avelumab
1
apatorsen
1
abemaciclib
1
Water
1
Thalidomide
1
Surveys and Questionnaires
1
Saline Solution
1
Rocuronium
1
Nephroureterectomy
1
Nephrectomy
1
Neoadjuvant Therapy
1
Mitomycin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Urologic Neoplasms
×
enfortumab vedotin
×
Clear all
NCT03219333
2024-08-27
EV-201
Astellas Pharma Inc
Phase 2
Completed
219 enrolled
32 charts
2 FDA